Musculoskeletal longevity reframes degenerative joint disease management toward preserving function and sustaining activity over time. Injection-based strategies have progressively evolved from hyaluronic acid (HA) viscosupplementation to autologous platelet-rich plasma (PRP), and further to PRP+HA combination approaches—aiming to integrate mechanical support with autologous biological signalling. 

This lecture proposes a structured continuum—HA → PRP → PRP+HA → regenerative matrices—to help clinicians contextualise current approaches and the emerging “next step” in longevity-oriented care. As an evidence anchor, the session reviews a prospective randomised controlled clinical comparison in knee osteoarthritis evaluating a PRP+HA cellular matrix approach versus HA-only regimens, using validated pain and functional measures across follow-up timepoints.  

A core challenge in orthobiologics remains the heterogeneity of PRP formulations and protocols, which limits comparability across trials and complicates translation to clinical practice. The lecture therefore highlights why standardisation and clear reporting are essential for reproducibility and credible adoption.   

Finally, the session briefly illustrates how translation can extend beyond clinic-level decisions into health-system evaluation, using Serbia’s osteoarthritis programme pathway described as progressing through national review and reimbursement consideration.  

The session concludes with practical takeaways on interpretation of evidence, the role of standardised preparation, and how regenerative matrices may shape future MSK longevity strategies.